Press releaseGlobe Newswire
Telomir Pharmaceuticals
TELO · NASDAQ
$1.01−$0.03 (−2.88%)TodayMarket closed ·
Prev close $1.04
Latest news
- Press releaseGlobe Newswire
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
- Press releaseGlobe Newswire
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
- Press releaseGlobe Newswire
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
- NewsAniket Verma
Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
- News
Market-Moving News for October 9th
- NewsAvi Kapoor
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- NewsRishabh Mishra
Stock Market Today: Dow Jones, Nasdaq 100, S&P 500 Futures Turn Green—Trilogy Metals, AMD, Applovin In Focus (UPDATED)
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
- News
Market-Moving News for October 7th
- NewsAvi Kapoor
McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday
- NewsMohd Haider
What's Behind The Sharp 39% After-Hours Rally In Telomir Pharmaceuticals?
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
- News
Watching Telomir Pharmaceuticals; Zacks Small-Cap Research Reaffirms $15.50 Price Valuation
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsRishabh Mishra
Stock Market Today: Nvidia Drags Down Nasdaq Futures, Dow Trades Higher—Dollar General, Dell, Best Buy In Focus (UPDATED)
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
- News
Market-Moving News for August 28th
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
Watching Telomir Pharmaceuticals; Zacks Small-Cap Research Gives Stock $15.50 Price Valuation
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
- Press releaseACCESS Newswire
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.